{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:50:11Z","timestamp":1794624611587,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was sponsored by Alkermes, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Schizophrenia (SZ) and bipolar I disorder (BD-I) are chronic mental health disorders often treated with antipsychotic medications. This qualitative study sought to better understand disease burden and treatment experiences with oral antipsychotic medications in participants living with SZ or BD-I.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Six 90-min focus groups were conducted with participants diagnosed with SZ or BD-I. Trained moderators facilitated discussions using a semistructured guide. Participants described symptoms, impacts of disease, and experiences with oral antipsychotic medications, whether favourable or unfavourable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among participants with SZ (<jats:italic>n<\/jats:italic>\u2009=\u200915; 3 groups, 5 per group), 53% were male and 33% were white, with a mean of 18.6\u00a0years since diagnosis. Of participants with BD-I (<jats:italic>n<\/jats:italic>\u2009=\u200924; 3 groups, 8 per group), 33% were male and 42% were white, with a mean of 13.0\u00a0years since diagnosis. Participants described numerous symptoms of their illnesses that impacted relationships and daily life, including effects on emotional health, the ability to work, and encounters with law enforcement. Previous antipsychotic medications were deemed effective by 14\/15 (93%) participants with SZ and 12\/16 (75%) participants with BD-I. Most participants with SZ (13\/15; 87%) or with BD-I (16\/24; 67%) reported discontinuing their antipsychotic medication at some point. Side effects were a common reason for discontinuing or switching medications for participants with SZ (8\/15; 53%) and for those with BD-I (11\/24; 46%). The most common side effects reported in both cohorts were weight gain, drowsiness, sexual problems, and neurologic symptoms. Side effects negatively affected quality of life, leading to serious health problems and issues with self-esteem.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>People living with SZ or BD-I cited a range of favourable and unfavourable experiences with oral antipsychotic medications. Most participants reported that their antipsychotics were effective at controlling their symptoms, but multiple side effects impacted their quality of life, caused additional serious health problems, and often led to discontinuation of or switching antipsychotics. Findings from this study contribute to a better understanding of patients\u2019 experiences with antipsychotics and highlight a need for new medications with favourable benefit\/risk profiles.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-023-04746-4","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:03:03Z","timestamp":1681297383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups"],"prefix":"10.1186","volume":"23","author":[{"given":"Michael J.","family":"Doane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Saucier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Bessonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April Mitchell","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"LaGasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Carpenter-Conlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sajatovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn I.","family":"Velligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"issue":"9","key":"4746_CR1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamapsychiatry.2013.1394","volume":"70","author":"C Crump","year":"2013","unstructured":"Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70(9):931\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.1394.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"4746_CR2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1176\/appi.ajp.2012.12050599","volume":"170","author":"C Crump","year":"2013","unstructured":"Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324\u201333. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12050599.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"4746_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","volume":"72","author":"ER Walker","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334\u201341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2502.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"4746_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137\u201350. https:\/\/doi.org\/10.1016\/s2215-0366(21)00395-3.","journal-title":"Lancet Psychiatry."},{"issue":"6","key":"4746_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.15m10278","volume":"77","author":"M Cloutier","year":"2016","unstructured":"Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764\u201371. https:\/\/doi.org\/10.4088\/JCP.15m10278.","journal-title":"J Clin Psychiatry"},{"key":"4746_CR6","doi-asserted-by":"publisher","unstructured":"Bessonova L, Ogden K, Doane MJ, O\u2019Sullivan AK, Tohen M. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481\u201397. https:\/\/doi.org\/10.2147\/CEOR.S259338.","DOI":"10.2147\/CEOR.S259338"},{"issue":"1","key":"4746_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/03007995.2020.1841618","volume":"37","author":"B Crespo-Facorro","year":"2021","unstructured":"Crespo-Facorro B, Such P, Nylander AG, Madera J, Resemann HK, Worthington E, et al. The burden of disease in early schizophrenia\u2014a systematic literature review. Curr Med Res Opin. 2021;37(1):109\u201321. https:\/\/doi.org\/10.1080\/03007995.2020.1841618.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"4746_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1399-5618.2011.00969.x","volume":"14","author":"WW IsHak","year":"2012","unstructured":"IsHak WW, Brown K, Aye SS, Kahloon M, Mobaraki S, Hanna R. Health-related quality of life in bipolar disorder. Bipolar Disord. 2012;14(1):6\u201318. https:\/\/doi.org\/10.1111\/j.1399-5618.2011.00969.x.","journal-title":"Bipolar Disord"},{"issue":"2","key":"4746_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152\u201363. https:\/\/doi.org\/10.1176\/appi.ajp.2008.08030368.","journal-title":"Am J Psychiatry"},{"key":"4746_CR10","volume-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia","author":"American Psychiatric Association","year":"2021","unstructured":"American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Association; 2021."},{"issue":"10027","key":"4746_CR11","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/s0140-6736(15)00241-x","volume":"387","author":"I Grande","year":"2016","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(15)00241-x.","journal-title":"Lancet"},{"issue":"1","key":"4746_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12888-021-03220-3","volume":"21","author":"A Kadakia","year":"2021","unstructured":"Kadakia A, Dembek C, Heller V, Singh R, Uyei J, Hagi K, et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry. 2021;21(1):249. https:\/\/doi.org\/10.1186\/s12888-021-03220-3.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"4746_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0020764015585330","volume":"62","author":"CR Medici","year":"2016","unstructured":"Medici CR, Vestergaard CH, Hjorth P, Hansen MV, Shanmuganathan JW, Viuff AG, et al. Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia. Int J Soc Psychiatry. 2016;62(1):12\u201320. https:\/\/doi.org\/10.1177\/0020764015585330.","journal-title":"Int J Soc Psychiatry"},{"issue":"2","key":"4746_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609.","journal-title":"Bipolar Disord"},{"issue":"1","key":"4746_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13696998.2018.1543188","volume":"22","author":"MS Broder","year":"2019","unstructured":"Broder MS, Greene M, Chang E, Hartry A, Yan T, Yermilov I. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder. J Med Econ. 2019;22(1):63\u201370. https:\/\/doi.org\/10.1080\/13696998.2018.1543188.","journal-title":"J Med Econ"},{"issue":"9","key":"4746_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/phar.1634","volume":"35","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy. 2015;35(9):813\u201322. https:\/\/doi.org\/10.1002\/phar.1634.","journal-title":"Pharmacotherapy"},{"issue":"9831","key":"4746_CR17","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/s0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(12)60239-6.","journal-title":"Lancet"},{"issue":"20","key":"4746_CR18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314.","journal-title":"Drugs"},{"key":"4746_CR19","doi-asserted-by":"publisher","unstructured":"Young SL, Taylor M, Lawrie SM. \u201cFirst do no harm.\u201d A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29(4):353\u201362. https:\/\/doi.org\/10.1177\/0269881114562090.","DOI":"10.1177\/0269881114562090"},{"issue":"1","key":"4746_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12888-022-03758-w","volume":"22","author":"MJ Doane","year":"2022","unstructured":"Doane MJ, Bessonova L, Friedler HS, Mortimer KM, Cheng H, Brecht T, et al. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022;22(1):114. https:\/\/doi.org\/10.1186\/s12888-022-03758-w.","journal-title":"BMC Psychiatry"},{"key":"4746_CR21","doi-asserted-by":"publisher","unstructured":"Doane MJ, Sajatovic M, Weiden PJ, O\u2019Sullivan AK, Maher S, Bjorner JB, et al. Antipsychotic treatment experiences of people with schizophrenia: patient perspectives from an online survey. Patient Prefer Adherence. 2020;14:2043\u201354. https:\/\/doi.org\/10.2147\/ppa.s270020.","DOI":"10.2147\/ppa.s270020"},{"key":"4746_CR22","doi-asserted-by":"publisher","unstructured":"Bessonova L, Velligan DI, Weiden PJ, O\u2019Sullivan AK, Yarlas A, Bayliss M, et al. Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020;20(1):354. https:\/\/doi.org\/10.1186\/s12888-020-02767-x.","DOI":"10.1186\/s12888-020-02767-x"},{"issue":"9618","key":"4746_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/s0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(08)60486-9.","journal-title":"Lancet"},{"issue":"1","key":"4746_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4088\/jcp.v69n0107","volume":"69","author":"MR Law","year":"2008","unstructured":"Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47\u201353. https:\/\/doi.org\/10.4088\/jcp.v69n0107.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"4746_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.psychres.2011.04.016","volume":"190","author":"J Hong","year":"2011","unstructured":"Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic\/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res. 2011;190(1):110\u20134. https:\/\/doi.org\/10.1016\/j.psychres.2011.04.016.","journal-title":"Psychiatry Res"},{"issue":"7","key":"4746_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2165\/11535200-000000000-00000","volume":"28","author":"J Hong","year":"2010","unstructured":"Hong J, Reed C, Novick D, Haro JM, Windmeijer F, Knapp M. The cost of relapse for patients with a manic\/mixed episode of bipolar disorder in the EMBLEM study. Pharmacoeconomics. 2010;28(7):555\u201366. https:\/\/doi.org\/10.2165\/11535200-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"4746_CR27","doi-asserted-by":"publisher","unstructured":"Kitzinger J. Qualitative research. Introducing focus groups. BMJ. 1995;311(7000):299\u2013302. https:\/\/doi.org\/10.1136\/bmj.311.7000.299.","DOI":"10.1136\/bmj.311.7000.299"},{"key":"4746_CR28","unstructured":"Krueger RA. Designing and Conducting Focus Group Interviews. Eastern Illinois University Illinois Higher Education Center. [https:\/\/www.eiu.edu\/ihec\/Krueger-FocusGroupInterviews.pdf]. Accessed 28 Sept 2021."},{"issue":"10","key":"4746_CR29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/1049732318821692","volume":"29","author":"MM Hennink","year":"2019","unstructured":"Hennink MM, Kaiser BN, Weber MB. What influences saturation? Estimating sample sizes in focus group research. Qual Health Res. 2019;29(10):1483\u201396. https:\/\/doi.org\/10.1177\/1049732318821692.","journal-title":"Qual Health Res"},{"issue":"3","key":"4746_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/nhs.12048","volume":"15","author":"M Vaismoradi","year":"2013","unstructured":"Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398\u2013405. https:\/\/doi.org\/10.1111\/nhs.12048.","journal-title":"Nurs Health Sci"},{"issue":"4","key":"4746_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/1049732305285972","volume":"16","author":"D Walker","year":"2006","unstructured":"Walker D, Myrick F. Grounded theory: an exploration of process and procedure. Qual Health Res. 2006;16(4):547\u201359. https:\/\/doi.org\/10.1177\/1049732305285972.","journal-title":"Qual Health Res"},{"issue":"12","key":"4746_CR32","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"4746_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/00325481.2019.1701823","volume":"132","author":"AM Meftah","year":"2020","unstructured":"Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. Postgrad Med. 2020;132(1):80\u201390. https:\/\/doi.org\/10.1080\/00325481.2019.1701823.","journal-title":"Postgrad Med"},{"issue":"10","key":"4746_CR34","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1176\/appi.ps.53.10.1319","volume":"53","author":"M Sajatovic","year":"2002","unstructured":"Sajatovic M, Rosch DS, Sivec HJ, Sultana D, Smith DA, Alamir S, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv. 2002;53(10):1319\u201321. https:\/\/doi.org\/10.1176\/appi.ps.53.10.1319.","journal-title":"Psychiatr Serv"},{"issue":"5\u20136","key":"4746_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.eurpsy.2005.02.006","volume":"20","author":"A Hofer","year":"2005","unstructured":"Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry. 2005;20(5\u20136):395\u2013402. https:\/\/doi.org\/10.1016\/j.eurpsy.2005.02.006.","journal-title":"Eur Psychiatry"},{"key":"4746_CR36","doi-asserted-by":"crossref","unstructured":"Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, et al. Compliance in schizophrenia: psychopathology, side effects, and patients\u2019 attitudes toward the illness and medication. J Clin Psychiatry. 2004;65(9):1211\u20138.","DOI":"10.4088\/JCP.v65n0908"},{"key":"4746_CR37","unstructured":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services, Food and Drug Administration. [http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf]. Accessed 8 Feb 2023."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04746-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04746-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04746-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:06:01Z","timestamp":1681297561000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04746-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4746"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04746-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were developed and carried out in accordance with industry best practices and relevant guidelines and regulations. The study protocol was approved by the New England Independent Review Board, and informed consent was obtained from all participants before the focus groups were conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.J. Doane is an employee of Alkermes, Inc., and may own stock\/options in the company. A.K. O'Sullivan, J. Carpenter-Conlin, and L. Bessonova were employees of Alkermes, Inc., at the time of this research and may own stock\/options in the company. C. Saucier, M.K. White, A.M. Foster, K. Raymond, and K. LaGasse have conducted research sponsored by Alkermes, Inc. M. Sajatovic and D.I. Velligan serve as consultants for Alkermes, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}